Literature DB >> 19402075

Hereditary kidney cancer: unique opportunity for disease-based therapy.

W Marston Linehan1, Peter A Pinto, Gennady Bratslavsky, Elizabeth Pfaffenroth, Maria Merino, Cathy D Vocke, Jorge R Toro, Donald Bottaro, Len Neckers, Laura S Schmidt, Ramaprasad Srinivasan.   

Abstract

Kidney cancer is not a single disease; it is comprised of several different types of cancer, each with a different histology, with a different clinical course, caused by a different gene, and responding differently to therapy. The VHL gene is the gene for the hereditary cancer syndrome, von Hippel-Lindau, as well as for the common form of sporadic, noninherited, clear cell kidney cancer. Understanding the VHL-hypoxia inducible factor (HIF) pathway has provided the foundation for the development of several agents targeting this pathway, such as sunitinib, sorafenib, and temsirolimus. Hereditary papillary renal carcinoma (HPRC) is a hereditary renal cancer syndrome in which affected individuals are at risk for the development of bilateral, multifocal, type 1 papillary renal cell carcinoma. The genetic defect underlying HPRC is MET, the cell surface receptor for hepatocyte growth factor. Mutations of MET also have been identified in a subset of tumors from patients with sporadic type 1 papillary renal cell carcinoma (RCC). Clinical trials targeting the MET pathway are currently underway in patients with HPRC and in patients with sporadic (nonhereditary) papillary kidney cancer. The BHD gene (also known as folliculin or FLCN) is the gene for Birt-Hogg-Dube syndrome, an autosomal-dominant genodermatosis associated with a hereditary form of chromophobe and oncocytic, hybrid RCC. Preclinical studies are underway targeting the BHD gene pathway in preparation for clinical trials in Birt-Hogg-Dube and sporadic chromophobe RCC. Patients with hereditary leiomyomatosis RCC (HLRCC) are at risk for developing cutaneous and uterine leiomyomas and a very aggressive type of RCC. HLRCC is characterized by germline mutation of the Krebs cycle enzyme, fumarate hydratase (FH). Studies of the tricarboxylic acid cycle and the VHL-HIF pathways have provided the foundation for therapeutic approaches in patients with HLRCC-associated kidney cancer as well as other hereditary and sporadic forms of RCC.

Entities:  

Mesh:

Year:  2009        PMID: 19402075      PMCID: PMC2720093          DOI: 10.1002/cncr.24230

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  64 in total

1.  High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.

Authors:  Cathy D Vocke; Youfeng Yang; Christian P Pavlovich; Laura S Schmidt; Michael L Nickerson; Carlos A Torres-Cabala; Maria J Merino; McClellan M Walther; Berton Zbar; W Marston Linehan
Journal:  J Natl Cancer Inst       Date:  2005-06-15       Impact factor: 13.506

2.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.

Authors:  I A Lubensky; L Schmidt; Z Zhuang; G Weirich; S Pack; N Zambrano; M M Walther; P Choyke; W M Linehan; B Zbar
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome.

Authors:  Christian P Pavlovich; Robert L Grubb; Kathleen Hurley; Gladys M Glenn; Jorge Toro; Laura S Schmidt; Carlos Torres-Cabala; Maria J Merino; Berton Zbar; Peter Choyke; McClellan M Walther; W Marston Linehan
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

4.  Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome.

Authors:  Laura S Schmidt; Michael L Nickerson; Michelle B Warren; Gladys M Glenn; Jorge R Toro; Maria J Merino; Maria L Turner; Peter L Choyke; Nirmala Sharma; James Peterson; Patrick Morrison; Eamonn R Maher; McClellan M Walther; Berton Zbar; W Marston Linehan
Journal:  Am J Hum Genet       Date:  2005-04-25       Impact factor: 11.025

Review 5.  Hereditary leiomyomatosis and renal cell cancer (HLRCC).

Authors:  Maija Kiuru; Virpi Launonen
Journal:  Curr Mol Med       Date:  2004-12       Impact factor: 2.222

6.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

Review 7.  Hereditary papillary renal cell carcinoma.

Authors:  B Zbar; K Tory; M Merino; L Schmidt; G Glenn; P Choyke; M M Walther; M Lerman; W M Linehan
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

8.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications.

Authors:  M M Walther; I A Lubensky; D Venzon; B Zbar; W M Linehan
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

9.  Parenchymal sparing surgery in patients with hereditary renal cell carcinoma.

Authors:  M M Walther; P L Choyke; G Weiss; C Manolatos; J Long; R Reiter; R B Alexander; W M Linehan
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

10.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

View more
  31 in total

Review 1.  Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.

Authors:  Bulent Cetin; Alim Kosar
Journal:  Int Urol Nephrol       Date:  2019-08-29       Impact factor: 2.370

Review 2.  Hereditary kidney cancer syndromes.

Authors:  Naomi B Haas; Katherine L Nathanson
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

3.  The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma.

Authors:  Summer S Han; Meredith Yeager; Lee E Moore; Ming-Hui Wei; Ruth Pfeiffer; Ousmane Toure; Mark P Purdue; Mattias Johansson; Ghislaine Scelo; Charles C Chung; Valerie Gaborieau; David Zaridze; Kendra Schwartz; Neonilia Szeszenia-Dabrowska; Faith Davis; Vladimir Bencko; Joanne S Colt; Vladimir Janout; Vsevolod Matveev; Lenka Foretova; Dana Mates; M Navratilova; Paolo Boffetta; Christine D Berg; Robert L Grubb; Victoria L Stevens; Michael J Thun; W Ryan Diver; Susan M Gapstur; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Laurie Burdett; Antonin Brisuda; James D McKay; Joseph F Fraumeni; Nilanjan Chatterjee; Philip S Rosenberg; Nathaniel Rothman; Paul Brennan; Wong-Ho Chow; Margaret A Tucker; Stephen J Chanock; Jorge R Toro
Journal:  Hum Mol Genet       Date:  2011-11-23       Impact factor: 6.150

4.  The changing face of renal-cell carcinoma.

Authors:  Gennady Bratslavsky; Ziya Kirkali
Journal:  J Endourol       Date:  2010-05       Impact factor: 2.942

5.  Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Megan Keane-Tarchichi; Michael Goldfischer; Lisa Edelmann; Youfeng Yang; W Marston Linehan; Maria J Merino; Seena Aisner; Meera Hameed
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

6.  Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.

Authors:  Jian Wu; Yuchen Jiao; Marco Dal Molin; Anirban Maitra; Roeland F de Wilde; Laura D Wood; James R Eshleman; Michael G Goggins; Christopher L Wolfgang; Marcia I Canto; Richard D Schulick; Barish H Edil; Michael A Choti; Volkan Adsay; David S Klimstra; G Johan A Offerhaus; Alison P Klein; Levy Kopelovich; Hannah Carter; Rachel Karchin; Peter J Allen; C Max Schmidt; Yoshiki Naito; Luis A Diaz; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-08       Impact factor: 11.205

7.  Canadian guideline on genetic screening for hereditary renal cell cancers.

Authors:  M Neil Reaume; Gail E Graham; Eva Tomiak; Suzanne Kamel-Reid; Michael A S Jewett; Georg A Bjarnason; Normand Blais; Melanie Care; Darryl Drachenberg; Craig Gedye; Ronald Grant; Daniel Y C Heng; Anil Kapoor; Christian Kollmannsberger; Jean-Baptiste Lattouf; Eamonn R Maher; Arnim Pause; Dean Ruether; Denis Soulieres; Simon Tanguay; Sandra Turcotte; Philippe D Violette; Lori Wood; Joan Basiuk; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 8.  Renal cell carcinoma: Evolving and emerging subtypes.

Authors:  Suzanne M Crumley; Mukul Divatia; Luan Truong; Steven Shen; Alberto G Ayala; Jae Y Ro
Journal:  World J Clin Cases       Date:  2013-12-16       Impact factor: 1.337

9.  PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Authors:  James Brugarolas
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

Review 10.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.